Lipocine Inc. Stock: price and insider trades · United States
1 insider bought €72k of shares over the last 90 days, the latest by Higuchi John W., filed 01 Oct 2026.
Lipocine Inc.: what insiders have been doing
Lipocine Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Between 24 October 2025 and 24 October 2026, 2 insiders published 7 filings.
Only purchases show up on the open market, 7 purchases in all worth €448k, filed by 2 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Higuchi John W. filed the largest purchase, €218k, on 6 April 2026. The buyers include 1 senior executive and 1 chief executive.
In all, 3 purchases were made within 30 days of a purchase by another insider of the company. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The clock since the last published purchase (1 October 2026) now reads 38 days. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
Across the 3,167 companies tracked on its exchange, the median is 24 filings; at 7 filings, this issuer sits below that mark. Our records for Lipocine Inc. go back to 2013, with 38 purchases and 14 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 2.0 m USD and net income of -9.6 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Who traded when
BuySaleSince the insiders bought
- -32.4%Entry US$2.13 · Close 23 Oct 2026 US$1.44
- -28.0%Entry US$2.00 · Close 23 Oct 2026 US$1.44
- -24.8%Entry US$5.63 · Close at T+365 US$4.23
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 9,037 shares@ US$2.150.11% mcap4.7% of flowCommon stockSEC:0001493152-26-045400:0Canonical exit: 28 Dec 2026 (T+90)
- 15,970 shares@ US$2.230.20% mcap8.7% of flowCommon stockSEC:0001493152-26-045400:1Canonical exit: 29 Dec 2026 (T+90)
- 12,561 shares@ US$2.160.15% mcap7.6% of flowCommon stockSEC:0001493152-26-045185:0Canonical exit: 27 Dec 2026 (T+90)
- 40,000 shares@ US$2.0324.1% of flowCommon stockSEC:0001493152-26-015583:0Canonical exit: 6 Jul 2026 (T+90)
- 123,000 shares@ US$2.0575.9% of flowCommon stockSEC:0001493152-26-015361:0Canonical exit: 5 Jul 2026 (T+90)
- 25,000 shares@ US$2.0313.7% of flowCommon stockSEC:0001493152-26-015357:0Canonical exit: 5 Jul 2026 (T+90)
- 25,000 shares@ US$2.0213.7% of flowCommon stockSEC:0001493152-26-014959:0Canonical exit: 1 Jul 2026 (T+90)
- 991 shares0Common StockSEC:0001493152-24-009705:0
- 4,893 shares0Common StockSEC:0001493152-24-009707:0
- 8,706 shares@ US$5.0312.7% of flowCommon StockSEC:0001493152-23-019050:0Canonical exit: 23 Aug 2023 (T+90)
- 150,000 shares@ US$0.3213.8% of flowCommon StockSEC:0001493152-23-008943:0Canonical exit: 22 Jun 2023 (T+90)
- 4,000 shares@ US$0.34100.0% of flowCommon StockSEC:0001493152-23-008304:0Canonical exit: 18 Jun 2023 (T+90)
- 50,000 shares@ US$0.334.9% of flowCommon StockSEC:0001493152-23-008087:0Canonical exit: 15 Jun 2023 (T+90)
- 21,739 shares@ US$0.47100.0% of flowCommon stockSEC:0001493152-22-033841:0Canonical exit: 20 Feb 2023 (T+90)
- 75,000 shares@ US$0.398.8% of flowCommon StockSEC:0001493152-22-031971:0Canonical exit: 12 Feb 2023 (T+90)
- 100,000 shares@ US$0.4113.3% of flowCommon StockSEC:0001493152-22-026945:0Canonical exit: 26 Dec 2022 (T+90)
- 12,500 shares@ US$0.86100.0% of flowCommon StockSEC:0001493152-22-014199:0Canonical exit: 15 Aug 2022 (T+90)
- 50,000 shares@ US$0.769911.5% of flowCommon StockSEC:0001493152-22-014014:0Canonical exit: 14 Aug 2022 (T+90)
- 25,000 shares@ US$1.097.5% of flowCommon StockSEC:0001493152-21-029268:0Canonical exit: 16 Feb 2022 (T+90)
- 1,700 shares@ US$1.350.4% of flowCommon StockSEC:0001638599-21-000003:0
- 5,000 shares@ US$1.351.1% of flowCommon StockSEC:0001638599-21-000003:1
- 28,125 shares0Common StockSEC:0001638599-20-000976:0
- 7,500 shares0Common StockSEC:0001638599-20-000978:0
- 3,750 shares0Common StockSEC:0001638599-20-000981:0
- 5,625 shares0Common StockSEC:0001638599-20-000979:0
25 of 79 declarations
About Lipocine Inc.
Lipocine Inc. (NASDAQ: LPCN) is a U.S.-listed biopharmaceutical company headquartered in Salt Lake City, Utah, United States. The company was founded in 1997 and has built its business around proprietary oral drug-delivery technology designed to improve the way therapeutics are administered, particularly for products that benefit from a more convenient, patient-friendly oral profile. For investors, Lipocine should be viewed as a small-cap biotech with meaningful execution risk, where value creation depends on clinical development, regulatory milestones, and partnership-driven monetization rather than a broad commercial platform. ([ir.lipocine.com](https://ir.lipocine.com/overview))
Lipocine’s core strategy is to leverage its formulation and delivery expertise to create differentiated oral products aimed at large markets with unmet medical needs. Its most advanced and commercially relevant asset is TLANDO, an oral testosterone replacement therapy approved by the U.S. FDA for adult men with certain forms of hypogonadism. TLANDO is the company’s key marketed/potentially marketed franchise and has been central to a series of licensing and distribution agreements that extend the asset beyond the U.S. market. ([ir.lipocine.com](https://ir.lipocine.com/overview))
Read moreShow less
The broader pipeline remains development-stage. Lipocine’s lead R&D program is LPCN 1154, an oral brexanolone formulation in Phase 3 for postpartum depression. Additional candidates include LPCN 2101 and LPCN 2203 in neurology-focused opportunities, LPCN 2401 for obesity-related body-composition management, and LPCN 1148 and LPCN 1144, which target liver disease and metabolic-liver indications such as cirrhosis and MASH. This diversified pipeline gives the company multiple shots on goal, but it also means clinical readouts, regulatory interactions, and capital requirements are still major investor considerations. ([ir.lipocine.com](https://ir.lipocine.com/2025-05-06-Lipocine-Announces-License-and-Supply-Agreement-for-TLANDO-R-in-Brazil?utm_source=openai))
From a competitive standpoint, Lipocine is not trying to compete as a large integrated pharmaceutical company. Instead, it occupies a niche position as a formulation specialist focused on converting therapeutically valuable compounds into oral products with improved usability. That makes its competitive set partly direct, partly indirect: it competes against other oral formulations, but also against established injectable or alternative therapies in the same disease areas. The company’s operating footprint remains centered in the United States, although recent commercialization agreements have broadened its geographic reach into Brazil, Canada, South Korea, and GCC markets. ([stocktitan.net](https://www.stocktitan.net/sec-filings/LPCN/10-k-lipocine-inc-files-annual-report-cf3a12072666.html?utm_source=openai))
Recent catalysts have been especially important. In 2025, Lipocine advanced its Phase 3 postpartum-depression study for LPCN 1154, announced a Canadian New Drug Submission for TLANDO through its partner, and signed a license and supply agreement with Aché to commercialize TLANDO in Brazil. The company also issued multiple financial and operational updates through 2025 and into 2026, underscoring an active catalyst calendar. For French, Belgian, and Swiss investors, Lipocine is best understood as a speculative NASDAQ biotech with upside tied to clinical outcomes, partnership execution, and the company’s ability to maintain financing flexibility. ([ir.lipocine.com](https://ir.lipocine.com/overview))
